 BASEL, Switzerland BEIJING CAMBRIDGE, Mass.BUSINESS WIREBeiGene NASDAQ: BGNE; HKEX: 06160; SSE: 688235, a global biotechnology company, today announced that the U.S. Food and Drug Administration FDA has approved its Brutons tyrosine kinase inhibitor BTKi BRUKINSA zanubrutinib for the treatment of adult patients with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. With ...... 